Area of research
Neurology · Molecular Biology
Research interest
Research interests include Neuroblastoma Research and Treatments, PARP inhibition in cancer therapy, Cancer therapeutics and mechanisms, and Protein Degradation and Inhibitors.
Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine
The potential of PARP as a therapeutic target across pediatric solid malignancies
MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma
Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition
Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors
Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells
An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma
TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets
Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells
ALK positively regulates MYCN activity through repression of HBP1 expression
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
Epac-Rap Signaling Reduces Oxidative Stress in the Tubular Epithelium